文献速递心血管腹部技术与安全MR

心脏磁共振衍生细胞外容积映射追踪系统性AL淀粉样变性多器官治疗反应

Tracking Multiorgan Treatment Response in Systemic AL-Amyloidosis With Cardiac Magnetic Resonance Derived Extracellular Volume Mapping.
PubMed 文献 · JACC Cardiovasc Imaging · 2023-05-10

本研究纳入351例系统性轻链淀粉样变性患者,其中171例有随访影像,评估心脏磁共振细胞外容积(ECV)映射追踪多器官治疗反应及与预后的关联。基线心肌和肝脏ECV独立预测死亡率,治疗6个月时心肌和肝脏ECV变化独立预测死亡率,肝脏和脾脏消退较心脏更快。

要点

  • 基线心肌ECV(HR 1.03)和肝脏ECV(HR 1.03)独立预测死亡率。
  • 化疗后6个月心肌ECV变化(HR 1.11)和肝脏ECV变化(HR 1.07)独立预测死亡率。
  • 治疗6个月时肝脏和脾脏ECV消退较心肌更快,12个月时心肌消退比例增加。

核心结论

  • 多器官ECV定量能准确追踪治疗反应,显示不同器官消退速率不同,肝脏和脾脏较心脏消退更快;基线心肌和肝脏ECV及6个月时变化独立预测死亡率。

研究设计与样本

  • 研究纳入351例诊断时接受基线血清淀粉样P成分(SAP)闪烁显像和心脏磁共振的患者,其中171例有随访影像。

关键影像表现/征象

  • 诊断时ECV映射显示304例(87%)有心脏受累,114例(33%)有明显肝脏受累,147例(42%)有明显脾脏受累。
  • 肝脏和脾脏ECV与SAP闪烁显像评估的淀粉样负荷相关(分别为R=0.751,P<0.001;R=0.765,P<0.001)。
  • 系列测量显示ECV正确识别SAP闪烁显像肝、脾淀粉样负荷变化的比例分别为85%和82%。
  • 6个月时,血液学反应良好者中肝脏ECV消退(30%)和脾脏ECV消退(36%)多于心肌消退(5%)。
  • 12个月时,反应良好者中心肌消退(心脏32%、肝脏30%、脾脏36%)。

诊断标准与关键数值

  • 基线心肌ECV预测死亡率HR 1.03(95%CI 1.01-1.06),P=0.009;肝脏ECV HR 1.03(95%CI 1.01-1.05),P=0.001。
  • 化疗开始后6个月心肌ECV变化预测死亡率HR 1.11(95%CI 1.02-1.20),P=0.011;肝脏ECV变化HR 1.07(95%CI 1.01-1.13),P=0.014。

临床应用与阅片要点

  • 心肌ECV消退与中位N末端脑钠肽前体降低相关(P<0.001)。
  • 肝脏ECV消退与中位碱性磷酸酶降低相关(P=0.001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND: Systemic light chain amyloidosis is a multisystem disorder that commonly involves the heart, liver, and spleen. Cardiac magnetic resonance with extracellular volume (ECV) mapping provides a surrogate measure of the myocardial, liver, and spleen amyloid burden.

OBJECTIVES: The purpose of this study was to assess multiorgan response to treatment using ECV mapping, and assess the association between multiorgan treatment response and prognosis.

METHODS: The authors identified 351 patients who underwent baseline serum amyloid-P-component (SAP) scintigraphy and cardiac magnetic resonance at diagnosis, of which 171 had follow-up imaging.

RESULTS: At diagnosis, ECV mapping demonstrated that 304 (87%) had cardiac involvement, 114 (33%) significant hepatic involvement, and 147 (42%) significant splenic involvement. Baseline myocardial and liver ECV independently predict mortality (myocardial HR: 1.03 [95% CI: 1.01-1.06]; P = 0.009; liver HR: 1.03; [95% CI: 1.01-1.05]; P = 0.001). Liver and spleen ECV correlated with amyloid load assessed by SAP scintigraphy (R = 0.751; P < 0.001; R = 0.765; P < 0.001, respectively). Serial measurements demonstrated ECV correctly identified changes in liver and spleen amyloid load derived from SAP scintigraphy in 85% and 82% of cases, respectively. At 6 months, more patients with a good hematologic response had liver (30%) and spleen (36%) ECV regression than myocardial regression (5%). By 12 months, more patients with a good response demonstrated myocardial regression (heart 32%, liver 30%, spleen 36%). Myocardial regression was associated with reduced median N-terminal pro-brain natriuretic peptide (P < 0.001), and liver regression with reduced median alkaline phosphatase (P = 0.001). Changes in myocardial and liver ECV, 6 months after initiating chemotherapy, independently predict mortality (myocardial HR: 1.11 [95% CI: 1.02-1.20]; P = 0.011; liver HR: 1.07 [95% CI: 1.01-1.13]; P = 0.014).

CONCLUSIONS: Multiorgan ECV quantification accurately tracks treatment response and demonstrates different rates of organ regression, with the liver and spleen regressing more rapidly than the heart. Baseline myocardial and liver ECV and changes at 6 months independently predict mortality, even after adjusting for traditional predictors of prognosis.

来源:JACC Cardiovasc Imaging,查看原文。版权归原作者所有。

引用

  1. Ioannou, Patel, Martinez-Naharro, et al. Tracking Multiorgan Treatment Response in Systemic AL-Amyloidosis With Cardiac Magnetic Resonance Derived Extracellular Volume Mapping. JACC Cardiovasc Imaging. 2023. PMID: 37178079. doi:10.1016/j.jcmg.2023.02.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。